BR0108514A - Uso de inibidores de il-18 - Google Patents

Uso de inibidores de il-18

Info

Publication number
BR0108514A
BR0108514A BR0108514-0A BR0108514A BR0108514A BR 0108514 A BR0108514 A BR 0108514A BR 0108514 A BR0108514 A BR 0108514A BR 0108514 A BR0108514 A BR 0108514A
Authority
BR
Brazil
Prior art keywords
inhibitors
medicament
preparation
relates
prevention
Prior art date
Application number
BR0108514-0A
Other languages
English (en)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
Santer Van Deventer
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Original Assignee
Applied Research Systems
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Yeda Res & Dev filed Critical Applied Research Systems
Publication of BR0108514A publication Critical patent/BR0108514A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"USO DE INIBIDORES DE IL-18". A invenção refere-se ao uso de inibidores de IL-18 na preparação de um medicamento para tratamento e/ou prevenção da lesão do fígado. A invenção ainda refere-se ao uso de inibidores de IL-18 na preparação de um medicamento para tratamento e/ou prevenção de artrite, em particular artrite reumatóide. Além disto, a invenção refere-se ao uso de inibidores de IL-18 na preparação de um medicamento para tratamento e/ou prevenção de doenças inflamatória do intestino, em particular de doenças Crohn e colite ulcerativa.
BR0108514-0A 2000-02-21 2001-02-20 Uso de inibidores de il-18 BR0108514A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
BR0108514A true BR0108514A (pt) 2002-12-17

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108514-0A BR0108514A (pt) 2000-02-21 2001-02-20 Uso de inibidores de il-18

Country Status (31)

Country Link
US (1) US20030157094A1 (pt)
EP (1) EP1257292B1 (pt)
JP (1) JP4744763B2 (pt)
KR (3) KR20020086540A (pt)
CN (1) CN1322897C (pt)
AT (1) ATE506959T1 (pt)
AU (2) AU2001240636B8 (pt)
BG (1) BG66134B1 (pt)
BR (1) BR0108514A (pt)
CA (2) CA2399298C (pt)
CY (1) CY1111687T1 (pt)
CZ (1) CZ304485B6 (pt)
DE (1) DE60144514D1 (pt)
DK (1) DK1257292T3 (pt)
EA (1) EA005583B1 (pt)
EE (1) EE05423B1 (pt)
HK (1) HK1051965A1 (pt)
HR (1) HRP20020652A2 (pt)
HU (1) HU227752B1 (pt)
IL (2) IL151388A0 (pt)
ME (1) ME00546B (pt)
MX (1) MXPA02008079A (pt)
NO (1) NO331971B1 (pt)
NZ (3) NZ520122A (pt)
PL (1) PL206549B1 (pt)
PT (1) PT1257292E (pt)
RS (1) RS51737B (pt)
SI (1) SI1257292T1 (pt)
SK (1) SK288032B6 (pt)
TR (2) TR200502508T2 (pt)
WO (1) WO2001062285A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US20030008822A1 (en) * 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
WO2003045400A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
AU2004235595C1 (en) * 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20090004683A1 (en) 2004-06-30 2009-01-01 Atsuo Sekiyama Indicator Agent for Noninflammatory Stress Response and Use Thereof
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
BRPI0711908B8 (pt) 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
EP3978526A1 (en) * 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
JP2021527107A (ja) * 2018-06-14 2021-10-11 ユニベルシテ ドゥ ボルドー インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療
EP4371573A1 (en) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medicinal composition for treating inflammatory bowel disease
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
WO1998022137A1 (en) * 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
ATE506959T1 (de) 2011-05-15
EA005583B1 (ru) 2005-04-28
KR20070087256A (ko) 2007-08-27
CA2399298C (en) 2014-04-15
NO20023962L (no) 2002-08-20
CA2399298A1 (en) 2001-08-30
IL151388A (en) 2009-09-01
WO2001062285A1 (en) 2001-08-30
DE60144514D1 (de) 2011-06-09
HK1051965A1 (en) 2003-08-29
HUP0300061A3 (en) 2005-09-28
NO331971B1 (no) 2012-05-14
EP1257292B1 (en) 2011-04-27
EA200200890A1 (ru) 2003-02-27
NZ546294A (en) 2008-02-29
EE05423B1 (et) 2011-06-15
KR20020086540A (ko) 2002-11-18
DK1257292T3 (da) 2011-07-18
BG107018A (bg) 2003-09-30
KR20070057282A (ko) 2007-06-04
RS51737B (sr) 2011-10-31
CY1111687T1 (el) 2015-10-07
BG66134B1 (bg) 2011-06-30
JP2003523403A (ja) 2003-08-05
PL357554A1 (en) 2004-07-26
EE200200463A (et) 2003-12-15
HRP20020652A2 (en) 2004-12-31
CZ20022843A3 (cs) 2003-02-12
US20030157094A1 (en) 2003-08-21
TR200502508T2 (tr) 2007-04-24
HUP0300061A2 (hu) 2003-04-28
AU2001240636B8 (en) 2005-11-03
SI1257292T1 (sl) 2011-08-31
AU2001240636B2 (en) 2005-10-13
YU60402A (sh) 2005-09-19
NZ520122A (en) 2005-04-29
CN1404400A (zh) 2003-03-19
SK12082002A3 (sk) 2003-05-02
CA2683009A1 (en) 2001-08-30
HU227752B1 (en) 2012-02-28
PT1257292E (pt) 2011-07-05
EP1257292A1 (en) 2002-11-20
IL151388A0 (en) 2003-04-10
TR200202030T2 (tr) 2003-01-21
AU4063601A (en) 2001-09-03
CN1322897C (zh) 2007-06-27
JP4744763B2 (ja) 2011-08-10
NZ535299A (en) 2006-06-30
CZ304485B6 (cs) 2014-05-28
ME00546B (me) 2011-10-10
SK288032B6 (sk) 2012-12-03
PL206549B1 (pl) 2010-08-31
NO20023962D0 (no) 2002-08-20
CA2683009C (en) 2014-09-23
MXPA02008079A (es) 2003-02-27

Similar Documents

Publication Publication Date Title
BR0108514A (pt) Uso de inibidores de il-18
BR0109931A (pt) Composições farmacêuticas
DZ3165A1 (fr) Composition alimentaire ou pharmaceutique utiliseepour prevenir ou traiter l'hyperoxalurie.
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
PT1049480E (pt) Agente herbaceo antiviral
EP1116488A3 (en) Treatment of inflammatory Bowel disease
BR0211827A (pt) Uso de inibidores de il-18 em distúrbios de hipersensibilidade
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
WO2003026693A3 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
SE9902674D0 (sv) New composition
SE9902673D0 (sv) New composition

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) , LABO

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) , MERC

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM ART .8O COMBINADO COM ART. 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]